Literature DB >> 11781119

Risk tables for parkinsonism and Parkinson's disease.

Alexis Elbaz1, James H Bower, Demetrius M Maraganore, Shannon K McDonnell, Brett J Peterson, J Eric Ahlskog, Daniel J Schaid, Walter A Rocca.   

Abstract

We applied the incidence rates of parkinsonism and Parkinson's disease (PD) from Olmsted County, MN (1976-1990) to a hypothetical cohort undergoing the mortality rates observed in Minnesota, and computed the lifetime risk and the remaining lifetime risk of developing parkinsonism and PD. These risks were compared to cumulative incidences that do not take competing risks of death into account. The lifetime risk of developing parkinsonism from birth was 4.4% for men and 3.7% for women (ratio = 1.2). The corresponding risk of developing PD was 2.0% for men and 1.3% for women (ratio = 1.5). Because of the opposite effect of higher incidence and higher mortality rates in men, the lifetime risks were only slightly higher in men than in women. Lifetime cumulative incidences were consistently higher than lifetime risks; this difference was more pronounced in men and in older subjects. Lifetime risk estimates are useful in clinical practice, epidemiologic research, and public health.

Entities:  

Mesh:

Year:  2002        PMID: 11781119     DOI: 10.1016/s0895-4356(01)00425-5

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  104 in total

Review 1.  Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies.

Authors:  Dean Dluzen; Martin Horstink
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

Review 2.  Parkinson's disease in women: a call for improved clinical studies and for comparative effectiveness research.

Authors:  J M Pavon; H E Whitson; M S Okun
Journal:  Maturitas       Date:  2010-02-01       Impact factor: 4.342

3.  Co-occurrence of parkinsonism and dementia in clinical practice: relevant differential diagnoses.

Authors:  I Liepelt-Scarfone; M Jamour; W Maetzler
Journal:  Z Gerontol Geriatr       Date:  2012-01       Impact factor: 1.281

4.  The co-occurrence of early onset Parkinson disease and 22q11.2 deletion syndrome.

Authors:  Christina Zaleski; Anne S Bassett; Karen Tam; Andrea L Shugar; Eva W C Chow; Elizabeth McPherson
Journal:  Am J Med Genet A       Date:  2009-03       Impact factor: 2.802

Review 5.  Genetics of iron regulation and the possible role of iron in Parkinson's disease.

Authors:  Shannon L Rhodes; Beate Ritz
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

6.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

7.  Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease.

Authors:  Cornelis Blauwendraat; Demis A Kia; Lasse Pihlstrøm; Ziv Gan-Or; Suzanne Lesage; J Raphael Gibbs; Jinhui Ding; Roy N Alcalay; Sharon Hassin-Baer; Alan M Pittman; Janet Brooks; Connor Edsall; Sun Ju Chung; Stefano Goldwurm; Mathias Toft; Claudia Schulte; Dena Hernandez; Andrew B Singleton; Mike A Nalls; Alexis Brice; Sonja W Scholz; Nicholas W Wood
Journal:  Neurobiol Aging       Date:  2017-12-20       Impact factor: 4.673

Review 8.  Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues.

Authors:  J Scott Roberts; Wendy R Uhlmann
Journal:  Prog Neurobiol       Date:  2013-04-09       Impact factor: 11.685

9.  Early-onset Parkinsonian behaviors in female Pink1-/- rats.

Authors:  Julia M Marquis; Samantha E Lettenberger; Cynthia A Kelm-Nelson
Journal:  Behav Brain Res       Date:  2019-09-19       Impact factor: 3.332

10.  The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow.

Authors:  Ozlem Goker-Alpan; Joseph C Masdeu; Philip D Kohn; Angela Ianni; Grisel Lopez; Catherine Groden; Molly C Chapman; Brett Cropp; Daniel P Eisenberg; Emerson D Maniwang; Joie Davis; Edythe Wiggs; Ellen Sidransky; Karen F Berman
Journal:  Brain       Date:  2012-08       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.